Martin Shkreli, We Hardly Knew Ye

Actually, we know Martin Shkreli, CEO of KaloBios Pharmaceuticals (NASDAQ: KBIO), all too well. The brash young man was arrested by the Federal Bureau of Investigations yesterday in Manhattan, on charges of fraud relating to his days at a hedge. Just weeks before, as then-CEO of privately held Turing Pharmaceuticals, he became the poster child of drug price gougers, having boosted the price of a long-marketed generic drug by 5000%, from $13.50 per pill to $750. The revelations in a New York Times story brought swift recriminations from all sides, including presidential candidates. The most striking note for us, as health care database wonks, is that Shkreli launched his first biotech... Read More »